Patrick Gleason, PharmD, Director of Health Outcomes, Prime Therapeutics, says benefit design trends in specialty pharmacy show that the preferred specialty tier is generally a cost share of around one hundred dollars for a 30-day supply.
Patrick Gleason, PharmD, Director of Health Outcomes, Prime Therapeutics, says benefit design trends in specialty pharmacy show that the preferred specialty tier is generally a cost share of around one hundred dollars for a 30-day supply. When cost shares rise above one hundred dollars, they find a decrease in utilization, especially in the choice to initiate or continue therapy of adherent and persistent medications.
"The Barriers Are Real": Antoine Keller, MD, on Geography and Cardiovascular Health
April 18th 2025Health care disparities are often driven by where patients live, explained Antoine Keller, MD, as he discussed the complex, systematic hurdles that influence the health of rural communities.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Health Equity & Access Weekly Roundup: April 14, 2025
April 14th 2025From the potential impact of tariffs to the World Health Organization's year-long campaign launch focused on improving maternal and newborn health and addressing preventable deaths, here's the latest from the Center on Health Equity & Access.
Read More